ADCs and the yen lift every line
Daiichi Sankyo Company, Limited (TSE: 4568) reported consolidated results for the first half of FY3/2027, April 1 to September 30, 2026, on October 30, 2026 under IFRS. Revenue rose by about ¥191.9 billion, driven by its global flagship products Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan), with currency adding about ¥73.9 billion. Revenue at Daiichi Sankyo Inc. in the US rose 54.8% to about ¥422.6 billion on Enhertu and Datroway in the US and Europe, and the Asia, South and Central America unit rose 20.9% to about ¥142.5 billion on Enhertu in Brazil, while the Japan unit fell 6.9% to about ¥232.7 billion as Lixiana and other products declined. Research and development spending rose 10.7% to about ¥240.1 billion on investment in its five DXd ADCs, yet core operating profit still rose 46.9% to ¥221,331 million, with currency adding about ¥22.7 billion.
Restructuring cost below the core line; guidance held
Operating profit rose 34.4% to ¥193,795 million after restructuring costs for the EU Specialty Business Unit were booked outside core profit. Profit before tax rose 18.2% to ¥192,855 million and profit attributable to owners of the parent 15.8% to ¥151,534 million, or ¥83.22 per share against ¥70.55. Daiichi Sankyo kept its FY3/2027 forecast of revenue of ¥2,340,000 million (+10.2%), core operating profit of ¥360,000 million (+15.6%), operating profit of ¥320,000 million (+24.0%) and profit attributable to owners of the parent of ¥251,000 million (−10.3%). It raised the interim dividend to ¥50 from ¥39 and plans ¥50 at year end, an annual ¥100 against ¥78. Total assets were ¥4,258,626 million and the equity ratio 41.3%.
| Metric | H1 FY3/2027 | H1 FY3/2026 | Change |
|---|---|---|---|
| Revenue (¥ million) | 1,167,233 | 975,353 | +19.7% |
| Core operating profit (¥ million) | 221,331 | 150,690 | +46.9% |
| Operating profit (¥ million) | 193,795 | 144,237 | +34.4% |
| Pre-tax profit (¥ million) | 192,855 | 163,217 | +18.2% |
| Net profit attrib. to owners of parent (¥ million) | 151,534 | 130,814 | +15.8% |
| Comprehensive income (¥ million) | 143,679 | 139,509 | +3.0% |
| EPS (¥) | 83.22 | 70.55 | +18.0% |
| Total assets (¥ million) | 4,258,626 | 3,996,285 | +6.6% |
| Equity attrib. to owners of parent (¥ million) | 1,757,648 | 1,684,033 | +4.4% |
| Equity ratio | 41.3% | 42.1% | -0.8 pt |
| FY3/2027 guidance — revenue (¥ million) | 2,340,000 | — | +10.2% |
| FY3/2027 guidance — core operating profit (¥ million) | 360,000 | — | +15.6% |
| FY3/2027 guidance — operating profit (¥ million) | 320,000 | — | +24.0% |
| FY3/2027 guidance — net profit (¥ million) | 251,000 | — | -10.3% |
| Annual dividend per share (¥) | 100.00 | 78.00 | +28.2% |
JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.